The activity of sulfamethoxazole (SMX), trimethoprim (TMP), and the combination of the two was determined against a variety of anaerobic bacteria. Brucella agar was somewhat inhibitory for SMX and TMP but activity was good and equivalent in Diagnostic Sensitivity Test Agar (Oxoid) and Mueller-Hinton agar and the latter was selected for use in these studies. Co-trimoxazole is an antimicrobial agent recently introduced into the United States for the treatment of chronic urinary tract infections due to susceptible organisms, primarily gramnegative bacilli. This agent has also been used for some time in England and Europe for the treatment of pulmonary infections (4), typhoid fever (2), and gonorrhea (9). Co-trimoxazole is a fixed ratio combination of sulfamethoxazole (SMX) and trimethoprim (TMP). Antimicrobial activity depends upon synergism between SMX and TMP which both interfere with bacterial folic acid activity in the synthesis of nucleic acids, though at different sites (7).
Co-trimoxazole is an antimicrobial agent recently introduced into the United States for the treatment of chronic urinary tract infections due to susceptible organisms, primarily gramnegative bacilli. This agent has also been used for some time in England and Europe for the treatment of pulmonary infections (4), typhoid fever (2) , and gonorrhea (9) . Co-trimoxazole is a fixed ratio combination of sulfamethoxazole (SMX) and trimethoprim (TMP). Antimicrobial activity depends upon synergism between SMX and TMP which both interfere with bacterial folic acid activity in the synthesis of nucleic acids, though at different sites (7) .
We decided to investigate the potential for use of co-trimoxazole in the treatment of anaerobic infections by studying the activity of SMX and TMP individually and in combination against a variety of anaerobic bacteria. Since the in vitro activity of SMX and TMP is known to be media dependent (12) and since growth of anerobes may vary on different media we initially had to determine the most appropriate medium for these susceptibility studies. Subsequently, we used agar dilution and disk diffusion methods to determine the activity of SMX and TMP against anaerobes. (10 ,g/ml), whereas BA was supplemented with 5% sheep blood and vitamin K, (10 zg/ml).
MATERIALS AND METHODS
Agar dilution (Steer's replicator [101) and disk diffusion susceptibility tests were performed by using methods described by Sutter et al. (11) . Studies of combined SMX + TMP activity were done by the "checkerboard" method by using fixed and varying concentrations of each antimicrobial as described by Sabath (8) . SMX 
RESULTS
Anaerobes studied. Table 1 shows the number and kinds of anaerobic isolates studied. The susceptibility of 98 different isolates to SMX and TMP individually was determined by the agar dilution method. Seventy-two of these were included in "checkerboard" studies of combined SMX + TMP activity. A total of 32 isolates was studied by the disk diffusion method and 10 of these were Bacteroides fragilis.
Determination of appropriate medium. Initially, the activity of SMX and TMP in BA and MHA was studied by comparing the susceptibility of all 98 isolates in both media by using the agar dilution method. A difference of at least two dilutions in the MIC was considered evidence of a significant difference in antimicrobial activity in the two media. Table 2 shows that SMX was less active in BA than in MHA against 6 of 98 isolates and that TMP was less active in BA against 10 isolates. On the other hand, neither SMX nor TMP were less active in MHA than BA against any of the anaerobes. On the basis of these data suggesting decreased SMX and TMP activity in BA, this medium was eliminated from the study.
Similar agar dilution studies were carried out to compare the activity of SMX and TMP in MHA and DST against 20 anaerobic isolates (Table 3) . SMX and TMP were less active in DST than in MHA against one and two isolates, respectively. On the other hand, in no instance was either agent less active in MHA than in DST. On the basis of these data, we determined that there was no significant difference in antimicrobial activity between these two media, and selected MHA as our standard medium for concentrations of SMX and TMP (in combination) which would be considered therapeutically achievable and which approximate the 20: 1 concentration ratio thought to be optimum for synergism (25 Ag of SMX per ml and 1.56 ,ug of TMP per ml). The 66 resistant isolates were inhibited only by concentrations of SMX and TMP > (100 ,g/ml and 6.25 ,g/ml), respectively.
The results of disk diffusion susceptibility tests with 32 isolates are shown in Table 6 . There are no zone size standards for interpretation of disk tests with SMX, TMP, and the combination. However, 24, 28, and 16 isolates had no inhibition zones when tested with SMX (23.75 ,Ag), TMP (1.25 Mg), and combination (25 Mug) disks, respectively. These isolates would certainly be considered resistant. Eight, four, and five isolates exhibited inhibition zones > 13 mm, with SMX, TMP, and combination disks, respectively. These isolates might be considered susceptible or "moderately resistant" in some instances. There were 11 other isolates with zones around the combination disk but these could be attributed to inhibitory activity of one of the individual component agents rather than synergism of the combination. It should be noted that although the term "synergism" is used to denote enhanced activity with the combination disk, in some instances this activity may be due to additive antimicrobial activity rather than true synergism.
Correlation between MIC and zone sizes for individual agents was Although BA was not included in that study, a similar enriched media which allows good anaerobic growth (brain heart infusion) contained as much as 30.9 ug of thymidine per ml, whereas DST and MH broth formulations both contained less than 1.0 Mg of thymidine per ml. Excess thymidine content may be one of the factors contributing to BA inhibitory activity against SMX and TMP.
In conclusion, our studies indicate that the majority of anaerobes are not susceptible to SMX, TMP, or the combination, and suggest that co-trimoxazole will not be useful for treatment of anaerobic infections. There is at least one other conflicting report indicating susceptibility of B. fragilis-to co-trimoxazole. However, this agent should not be used to treat anaerobic infections until further experience with in vitro studies or experimental infections provides information which will help to resolve these questions.
